March 3, 2026Open Access

Hypercalcemia From Trenbolone Use: A Case Report

Key Points

Hypercalcemia improved significantly following treatment with intravenous fluids and pamidronate, indicating effective intervention.
The patient exhibited acute kidney injury, with creatinine levels reaching 6.02 mg/dL during assessment.
Case analysis ruled out common causes like malignancy and vitamin D toxicity, illustrating the need for comprehensive evaluation.
This highlights the potential dangers of anabolic-androgenic steroid use, particularly for metabolic and renal health.

Abstract

In this case, a patient presented to the emergency department (ED) with fatigue after CareNow noted abnormal laboratory results. The patient reported using trenbolone, an anabolic-androgenic steroid (AAS) often used for athletic performance enhancement or cosmetic purposes. In the ED, the patient was noted to have significant hypercalcemia (15 mg/dL) and acute kidney injury (AKI) (creatinine 6.02 mg/dL). The workup ruled out malignancy, hyperparathyroidism, and vitamin D toxicity. The patient was admitted and received intravenous fluids and pamidronate, which improved the patient's hypercalcemia and AKI. This case adds to the limited literature on metabolic and renal dysfunction associated with AAS use. Additionally, this case highlights the importance of a thorough history, including supplements and nonprescribed substances that patients may be using, as these can contribute significantly to their presentation and care.

Bookmark

View Full Paper